Jeffrey W Cooney
Assistant Professor of Neurology
I see patients with a broad range of movement disorders, including Parkinson's disease, tremors, ataxia, dystonia, tics, and Huntington's disease. I employ deep brain stimulation (DBS) therapy for selected patients with Parkinson's disease, tremor, or dystonia, and use botulinum toxin injections for certain patients with dystonia, tremors, or tics. I work with an interdisciplinary team of physicians, therapists, and other healthcare providers, with the overall goal of helping to improve the lives of patients with complex neurological diseases.
Current Appointments & Affiliations
- Assistant Professor of Neurology, Neurology, Movement Disorders, Neurology 2021
Contact Information
- Background
-
Education, Training, & Certifications
- M.D., University of North Carolina - Chapel Hill 2010
-
Previous Appointments & Affiliations
- Assistant Professor of Neurology, Neurology, Movement Disorders, Neurology 2015 - 2020
-
Leadership & Clinical Positions at Duke
- Director, Parkinson's Disease and Movement Disorders fellowship
- Recognition
-
In the News
-
MAY 11, 2018
-
- Research
-
Selected Grants
- 58 Week Open-Label Trial of Tavapadon in PD (TemPo-4 Trial) awarded by Cerevel Therapeutics 2020 - 2024
- A Double-Blind, Placebo-Controlled, Safety Tolerability and Pharmacokinetics Study in Parkinson¿s Disease Participants Treated with Carbidopa/Levodopa and NE3107 Phase 2a awarded by BioVie, Inc 2022 - 2023
- A Multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Pa awarded by NeuroDerm, Ltd 2019 - 2023
- Scalar Closed-Loop STN/GPi DBS Based on Evoked and Spontaneous Potentials awarded by National Institutes of Health 2017 - 2022
- Duke Parkinson's Disease and Movement Disorders Fellowship awarded by Abbott Cardiovascular Systems, Inc. 2021 - 2022
- Duke Parkinson's Disease and Movement Disorders Fellowship 2021-22 awarded by Medtronic Foundation 2021 - 2022
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON'S DISEASE (TEMPO-1 TRIAL) awarded by Cerevel Therapeutics 2020 - 2021
- Jeff Cooney Boston Scientific awarded by Boston Scientific Corporation 2020 - 2021
- Mitochondrial DNA damage as a blood-based biomarker of early Parkinson's disease awarded by Michael J. Fox Foundation for Parkinson's Research 2017 - 2019
- PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF BTRX-246040 IN PARKINSON'S DISEASE SUBJECTS WITH MOTOR FLUCTUATIONS ( PROTOCOL NEP-PD-201) awarded by BlackThorn Therapeutics 2018 - 2019
- Protecting Neurodevelopment in Latino Migrant Children by Reduced Exposure to Organophosphate Pesticides awarded by National Institutes of Health 2017 - 2019
- A Phase 2a, Double-Blind, Placebo-Controlled, Two-Part Study To Investigate the Safety And Efficacy Of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations awarded by Dart NeuroScience 2017 - 2018
- A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease (UBeyoNDU) awarded by NeuroDerm, Ltd 2017 - 2018
- A MultiCtr,OL,dosageranging study in early,untreated or stably treated subjects with Parkinson's PD to determine the safety,tolerability and PK of inj ofSER-214administered subcu once a week for two weeks after 0-2 weeks of dose titration. awarded by Serina Therapeutics, Inc. 2016 - 2017
-
External Relationships
- AbbVie Pharmaceuticals
- Medtronic Foundation
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Ratliff, Jeffrey B., Sara M. Schaefer, Shilpa Chitnis, Jeffrey W. Cooney, Christopher W. Hess, Njideka Okubadejo, Ali Shalash, et al. “Viewpoint on Milestones for Fellowship Training in Movement Disorders.” Mov Disord 37, no. 8 (August 2022): 1605–9. https://doi.org/10.1002/mds.29146.Full Text Open Access Copy Link to Item
-
Mitchell, Kyle T., Stephen L. Schmidt, Jeffrey W. Cooney, Warren M. Grill, Jennifer Peters, Shervin Rahimpour, Hui-Jie Lee, et al. “Initial Clinical Outcome With Bilateral, Dual-Target Deep Brain Stimulation Trial in Parkinson Disease Using Summit RC + S.” Neurosurgery 91, no. 1 (July 1, 2022): 132–38. https://doi.org/10.1227/neu.0000000000001957.Full Text Open Access Copy Link to Item
-
Sharma, Vibhash D., Delaram Safarpour, Shyamal H. Mehta, Nora Vanegas-Arroyave, Daniel Weiss, Jeffrey W. Cooney, Zoltan Mari, and Alfonso Fasano. “Telemedicine and Deep brain stimulation - Current practices and recommendations.” Parkinsonism Relat Disord 89 (August 2021): 199–205. https://doi.org/10.1016/j.parkreldis.2021.07.001.Full Text Link to Item
-
Shah-Zamora, Deepal, Allison M. Allen, Lacy Rardin, Margaret Ivancic, Katie Durham, Patrick Hickey, Jeffrey W. Cooney, Burton L. Scott, and Sneha Mantri. “Mindfulness based stress reduction in people with Parkinson's disease and their care partners.” Complement Ther Clin Pract 43 (May 2021): 101377. https://doi.org/10.1016/j.ctcp.2021.101377.Full Text Open Access Copy Link to Item
-
Gillette, Chris, Jeffrey W. Cooney, Caroline B. Sisson, Nicole Rockich-Winston, Courtney J. Perry, and Wendy C. Moore. “Levodopa inhalation powder in a patient with persistent asthma.” Parkinsonism Relat Disord 78 (September 2020): 44–45. https://doi.org/10.1016/j.parkreldis.2020.07.011.Full Text Open Access Copy Link to Item
-
Black, Kevin J., Henry Nasrallah, Stuart Isaacson, Mark Stacy, Rajesh Pahwa, Charles H. Adler, Gustavo Alva, et al. “Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.” Cns Spectr 23, no. 6 (December 2018): 402–13. https://doi.org/10.1017/S1092852918001359.Full Text Open Access Copy Link to Item
-
Potnis, Kunal C., Lauren B. Flueckinger, Stephanie M. DeArmey, Roy N. Alcalay, Jeffrey W. Cooney, and Priya S. Kishnani. “Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum.” Mol Genet Metab Rep 17 (December 2018): 69–72. https://doi.org/10.1016/j.ymgmr.2018.10.001.Full Text Open Access Copy Link to Item
-
Cooney, Jeffrey W., and Mark Stacy. “Neuropsychiatric Issues in Parkinson's Disease.” Curr Neurol Neurosci Rep 16, no. 5 (May 2016): 49. https://doi.org/10.1007/s11910-016-0647-4.Full Text Open Access Copy Link to Item
-
Badre, David, Joshua Hoffman, Jeffrey W. Cooney, and Mark D’Esposito. “Hierarchical cognitive control deficits following damage to the human frontal lobe.” Nat Neurosci 12, no. 4 (April 2009): 515–22. https://doi.org/10.1038/nn.2277.Full Text Link to Item
-
Gazzaley, Adam, Jesse Rissman, Jeffrey Cooney, Aaron Rutman, Tyler Seibert, Wesley Clapp, and Mark D’Esposito. “Functional interactions between prefrontal and visual association cortex contribute to top-down modulation of visual processing.” Cereb Cortex 17 Suppl 1, no. 0 1 (September 2007): i125–35. https://doi.org/10.1093/cercor/bhm113.Full Text Link to Item
-
Gazzaley, Adam, Margaret A. Sheridan, Jeffrey W. Cooney, and Mark D’Esposito. “Age-related deficits in component processes of working memory.” Neuropsychology 21, no. 5 (September 2007): 532–39. https://doi.org/10.1037/0894-4105.21.5.532.Full Text Link to Item
-
D’Esposito, Mark, Jeffrey W. Cooney, Adam Gazzaley, Sasha E. B. Gibbs, and Bradley R. Postle. “Is the prefrontal cortex necessary for delay task performance? Evidence from lesion and FMRI data.” J Int Neuropsychol Soc 12, no. 2 (March 2006): 248–60. https://doi.org/10.1017/S1355617706060322.Full Text Link to Item
-
Gazzaley, A., J. W. Cooney, J. Rissman, and M. D’Esposito. “Erratum: Top-down suppression deficit underlies working memory impairment in normal aging (Nature Neuroscience (2005) 8 (1298-1300)).” Nature Neuroscience 8, no. 12 (December 1, 2005): 1791. https://doi.org/10.1038/nn1205-1791c.Full Text
-
Gazzaley, Adam, Jeffrey W. Cooney, Jesse Rissman, and Mark D’Esposito. “Top-down suppression deficit underlies working memory impairment in normal aging.” Nat Neurosci 8, no. 10 (October 2005): 1298–1300. https://doi.org/10.1038/nn1543.Full Text Link to Item
-
Gazzaley, Adam, Jeffrey W. Cooney, Kevin McEvoy, Robert T. Knight, and Mark D’Esposito. “Top-down enhancement and suppression of the magnitude and speed of neural activity.” J Cogn Neurosci 17, no. 3 (March 2005): 507–17. https://doi.org/10.1162/0898929053279522.Full Text Link to Item
-
Cooney, Jeffrey W., and Michael S. Gazzaniga. “Neurological disorders and the structure of human consciousness.” Trends Cogn Sci 7, no. 4 (April 2003): 161–65. https://doi.org/10.1016/s1364-6613(03)00058-5.Full Text Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.